{
    "2021-06-07": [
        [
            {
                "time": "2023-10-05",
                "original_text": "AbbVie (ABBV) Gains As Market Dips: What You Should Know",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "gains",
                        "market dips"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "AbbVie's Ibrutinib/Venetoclax Combo Potentially Chemo-free, Fixed-Duration Treatment Option in Leukemia",
                "features": {
                    "keywords": [
                        "Ibrutinib",
                        "Venetoclax",
                        "chemo-free",
                        "leukemia"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "CAPTIVATE Study Shows an IMBRUVICA速 (ibrutinib) Plus VENCLEXTA速/VENCLYXTO速 (venetoclax) Chemotherapy-Free Combination Has Potential to Provide Remission After Fixed-Duration Treatment for Chronic Lymphocytic Leukemia (CLL)",
                "features": {
                    "keywords": [
                        "CAPTIVATE",
                        "IMBRUVICA",
                        "VENCLEXTA",
                        "chemotherapy-free",
                        "remission",
                        "CLL"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "oncology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Health Canada Approves AbbVie's RINVOQ速 (upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis",
                "features": {
                    "keywords": [
                        "Health Canada",
                        "RINVOQ",
                        "upadacitinib",
                        "psoriatic arthritis"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "rheumatology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}